CN105395702A - Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof - Google Patents
Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof Download PDFInfo
- Publication number
- CN105395702A CN105395702A CN201510899872.0A CN201510899872A CN105395702A CN 105395702 A CN105395702 A CN 105395702A CN 201510899872 A CN201510899872 A CN 201510899872A CN 105395702 A CN105395702 A CN 105395702A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- parts
- protecting
- liver
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 210000004185 liver Anatomy 0.000 title claims abstract description 16
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 8
- 206010019133 Hangover Diseases 0.000 title abstract 6
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 81
- 239000005017 polysaccharide Substances 0.000 claims abstract description 81
- 241001486992 Taiwanofungus camphoratus Species 0.000 claims abstract description 26
- 241000190633 Cordyceps Species 0.000 claims abstract description 25
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims abstract description 23
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 22
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000811 xylitol Substances 0.000 claims abstract description 22
- 235000010447 xylitol Nutrition 0.000 claims abstract description 22
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 22
- 229960002675 xylitol Drugs 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 150000004676 glycans Chemical class 0.000 claims abstract 21
- 230000002075 anti-alcohol Effects 0.000 claims description 32
- 108010001062 polysaccharide-K Proteins 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 23
- 238000002360 preparation method Methods 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 231100000753 hepatic injury Toxicity 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 4
- 231100000765 toxin Toxicity 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 206010067125 Liver injury Diseases 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 241000222356 Coriolus Species 0.000 abstract 1
- 208000006083 Hypokinesia Diseases 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 150000004804 polysaccharides Chemical class 0.000 description 60
- 230000003203 everyday effect Effects 0.000 description 30
- 230000037396 body weight Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 17
- 238000003304 gavage Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 7
- 229940046011 buccal tablet Drugs 0.000 description 6
- 239000006189 buccal tablet Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229920002527 Glycogen Polymers 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- -1 correctives Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000010117 shenhua Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof. The composition comprises the following components by mass: 10-15 parts of Cordyceps polysaccharide, 5-10 parts of Antrodia camphorate polysaccharide, 2-4 parts of Panax quinquefolium polysaccharide, 1-2 parts of Lycium barbarum polysaccharide, 0.5-1 part of Coriolus versciclor polysaccharide, 1-2 parts of Poria cocos polysaccharide, and 40-60 parts of xylitol. The composition with hangover alleviating, liver protecting and anti-fatigue efficacy can be applied to preparation of hangover alleviating, liver protecting and anti-fatigue drugs or food. The composition provided by the invention has hangover alleviating, liver protecting and anti-fatigue effects, also can inhibit the absorption of alcohol and toxins and accelerate the metabolism of toxins and alcohol in liver and kidney, thereby improving the body tolerance to alcohol. The composition adopts pure natural plant polysaccharide as the main component, is not added with chemical additive, can alleviate liver injury, hypodynamia and other symptoms caused by alcohol, and can achieve good hangover alleviating effect.
Description
Technical field
The present invention relates to relieving alcoholism and protecting the liver field of health care products, be specifically related to a kind of compositions and the application thereof with Antialcoholic liver-protecting resisting fatigue.
Background technology
Long-term heavy drinking can cause alcoholic liver injury, finally can develop into chronic active hepatitis even liver cirrhosis.Heavy drinking in the short-term a few days, also can cause lighter hepatic injury as alcoholic fatty liver.Concerning having basic type hepatopathy as the people of chronic hepatitis B, more want teetotalism, the very important risk factor making chronic hepatitis b disease feelings increase the weight of often because drink, simultaneously, ethanol affects human homergy, producing more metabolism rubbish cannot normal excretion, causes the state that human body is in fatigue, cannot concentrates one's energy.
Current antialcoholic drug generally adopts decomposing alcohol to play the effect of relieving the effect of alcohol, and effect of relieving the effect of alcohol is slow, can only alleviate alcohol concentration in human body too high and cause the symptom of human body discomfort, but not have health-care effect to the lesions of liver and kidney that ethanol causes.Ethanol is after liver metabolism, unwanted metabolic products can be produced as acetaldehyde, if do not accelerated metabolism, the excretion of acetaldehyde, can cause more serious kidney injury, simultaneously in order to improve effect of relieving the effect of alcohol, existing antialcoholic drug usually adds chemical addition agent to improve the effect of relieving the effect of alcohol of antialcoholic drug, chemical addition agent is generally through liver metabolism, through renal excretion, long-term edible a large amount of food adding chemical addition agent, becomes the hidden danger of health.In addition, antialcoholic drug almost cannot alleviate the drink giddy produced, the symptom such as weak, absent minded, so hepatoprotective resisting fatigue need be focused on when modern white collar is drunk, could after drinking the liver protecting and do not affect normal work and study.
Summary of the invention
The object of the invention is to provide a kind of compositions and the application thereof with Antialcoholic liver-protecting resisting fatigue.Said composition adopts pure natural plant polysaccharide to be main component, does not add chemical addition agent, has the symptoms such as hepatic injury that alleviation of alcohol causes, health be weak, relieves the effect of alcohol effective.
The object of the invention is to realize in the following manner:
There is a compositions for Antialcoholic liver-protecting resisting fatigue, comprise each component of following mass parts: Cordyceps polysaccharide 10-15 part, Antrodia camphorata polysaccharide 5-10 part, Radix Panacis Quinquefolii polysaccharide 2-4 part, lycium barbarum polysaccharide 1-2 part, krestin 0.5-1 part, pachyman 1-2 part, xylitol 40-60 part.
There is a compositions for Antialcoholic liver-protecting resisting fatigue, preferably comprise each component of following mass parts: Cordyceps polysaccharide 11-14 part, Antrodia camphorata polysaccharide 6-9 part, Radix Panacis Quinquefolii polysaccharide 2-3.5 part, lycium barbarum polysaccharide 1-1.5 part, krestin 0.5-1 part, pachyman 1-2 part, xylitol 45-55 part.
There is a compositions for Antialcoholic liver-protecting resisting fatigue, preferably comprise each component of following mass parts: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 2 parts, xylitol 45 parts.
There is a compositions for Antialcoholic liver-protecting resisting fatigue, preferably comprise each component of following mass parts: Cordyceps polysaccharide 14 parts, Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 3 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 1 part, xylitol 50 parts.
There is a compositions for Antialcoholic liver-protecting resisting fatigue, preferably comprise each component of following mass parts: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 8 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 1 part, xylitol 60 parts.
The described compositions with Antialcoholic liver-protecting resisting fatigue is preparing the application in medicament for sobering up and protecting liver or food.
The described compositions with Antialcoholic liver-protecting resisting fatigue is preparing the application in anti-fatigue medicament or food.
The compositions with Antialcoholic liver-protecting resisting fatigue is made the dosage form on any one pharmaceutics.
Any one food form is made by having the compositions of Antialcoholic liver-protecting resisting fatigue and general food adjuvant and/or food additive.
Cordyceps polysaccharide described in the present invention, Radix Panacis Quinquefolii polysaccharide, Antrodia camphorata polysaccharide, lycium barbarum polysaccharide, krestin, pachyman, respectively from Cordyceps (Ophiocordycepssinensis), adopt general extraction methods extract and obtain in Radix Panacis Quinquefolii (PanaxquiquefoliumL), Antrodia camphorata (Antrodiacamphorata), Fructus Lycii (LyciumbarbarumL.), Coriolous Dersicolor (Fr.) Quel (Coriolusversicolor), Poria (PoriacocosWolf).Also can commercially obtain.
The described compositions with Antialcoholic liver-protecting resisting fatigue, can make various preparation as required, include but not limited to tablet, capsule, external preparation, Oral preparation, unguentum, suppository, powder, solution, granule, tincture etc.In these formulations except the above-mentioned various compositions of the present invention, the acceptable adjuvant of various medicine can also be added, include but not limited to: binding agent is as microcrystalline Cellulose, Tragacanth or gelatin; Excipient is as starch, chitosan, lactose; Disintegrating agent is as alginic acid, corn starch etc.; Lubricant is as magnesium stearate; Fluidizer is as colloidal silica; Pulvis Talci; Correctives is as sucrose or glucide etc.
Such as, the present composition is prepared into buccal tablet, adopts and prepare with the following method: get Cordyceps polysaccharide, Antrodia camphorata polysaccharide, Radix Panacis Quinquefolii polysaccharide, lycium barbarum polysaccharide, krestin, pachyman, mixing, adds xylitol, correctives, binding agent, dries, pulverizes, sieves, tabletting, to obtain final product.Be specially:
The present composition and correctives 1-5 part and binding agent 1-3 part are prepared as buccal tablet, and preparation method is as follows:
1) by Cordyceps polysaccharide, Antrodia camphorata polysaccharide, Radix Panacis Quinquefolii polysaccharide, lycium barbarum polysaccharide, krestin, pachyman is pulverized, cross 30 mesh sieves, obtains polysaccharide mixture; Xylitol was pulverized 40 mesh sieves, obtained Icing Sugar.
2) polysaccharide mixture and Icing Sugar mixed and stir, adding correctives, binding agent afterwards, continuing to stir, obtain soft material, then soft material is dried, tabletting, obtain buccal tablet.
Correctives can be Conventional flavoring agents in medicine, include but not limited to aspartame, cyclamate, glycyrrhizin, stevioside, glucide etc., described binding agent is Conventional flavoring agents in medicine, includes but not limited to gelatinized corn starch, starch, dextrin, Icing Sugar, Icing Sugar, Mel etc.
The consumption of instant component and each component is through inventor and gropes in a large number to sum up and draw, each amounts of components has good Antialcoholic liver-protecting anti-fatigue effect in above-mentioned scope, there is significantly collaborative raising effect, said components combination after, its effect relative to be used alone or other modes combinationally use time be significantly improved.
Beneficial effect:
Compositions provided by the invention have relieve the effect of alcohol, the effect of hepatoprotective, resisting fatigue, and ethanol and toxin absorption can be suppressed, accelerate the metabolism at liver and kidney of toxin and ethanol, thus improve body to the tolerance of ethanol.
Compositions provided by the invention can alleviate malaise symptoms of being still drank after a night, Yin Yang balancing metabolism, resisting fatigue, thus ensures body recovery function.
Said composition adopts pure natural plant polysaccharide to be main component, does not add chemical addition agent, has the symptoms such as hepatic injury that alleviation of alcohol causes, health be weak, relieves the effect of alcohol effective.
Detailed description of the invention
In following examples, Radix Panacis Quinquefolii polysaccharide is purchased from Ningbo Sino-Taipio Herbal Science Co., Ltd., pachyman is purchased from Wuhan Ding Hui Chemical Co., Ltd., and lycium barbarum polysaccharide, Cordyceps polysaccharide, Antrodia camphorata polysaccharide, krestin are purchased from Jiangsu Shenhua Medicine Co., Ltd.
Embodiment 1
There is the compositions of Antialcoholic liver-protecting resisting fatigue, comprise each component of following mass parts: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 2 parts, xylitol 45 parts.
Above-mentioned composition and correctives 1 part and binding agent 1 part are prepared as buccal tablet, and preparation method is as follows:
1) by Cordyceps polysaccharide, Antrodia camphorata polysaccharide, Radix Panacis Quinquefolii polysaccharide, lycium barbarum polysaccharide, krestin, pachyman is pulverized, cross 30 mesh sieves, obtains polysaccharide mixture.Xylitol was pulverized 40 mesh sieves, obtained Icing Sugar.
2) polysaccharide mixture and Icing Sugar mixed and stir, adding correctives, binding agent afterwards, continuing to stir, obtain soft material, then soft material is dried, tabletting, obtain buccal tablet.
Embodiment 2
There is the compositions of Antialcoholic liver-protecting resisting fatigue, comprise each component of following mass parts: Cordyceps polysaccharide 14 parts, Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 3 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 1 part, xylitol 50 parts.
Preparation method is with embodiment 1.
Embodiment 3
There is the compositions of Antialcoholic liver-protecting resisting fatigue, comprise each component of following mass parts: Cordyceps polysaccharide 10 parts, Antrodia camphorata polysaccharide 10 parts, Radix Panacis Quinquefolii polysaccharide 4 parts, lycium barbarum polysaccharide 2 parts, krestin 1 part, pachyman 2 parts, xylitol 40 parts.
Preparation method is with embodiment 1.
Embodiment 4
There is the compositions of Antialcoholic liver-protecting resisting fatigue, comprise each component of following mass parts: Cordyceps polysaccharide 15 parts, Antrodia camphorata polysaccharide 5 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 1 part, xylitol 40 parts.
Preparation method is with embodiment 1.
Embodiment 5
There is the compositions of Antialcoholic liver-protecting resisting fatigue, comprise each component of following mass parts: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 8 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 1 part, xylitol 60 parts.
Preparation method is with embodiment 1.
Matched group 1: Cordyceps polysaccharide 12 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, krestin 0.5 part, pachyman 2 parts, xylitol 45 parts.
Matched group 2: Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, krestin 0.5 part, pachyman 2 parts, xylitol 45 parts.
Matched group 3: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 6 parts, lycium barbarum polysaccharide 1 part, xylitol 45 parts.
Matched group 4: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part.
Embodiment 6 effect experimental
1) drunk tolerance test
Mice 18-22g, male, often organize 10, be divided into 8 groups: blank group of (distilled water, 1mL/ is every only/every day), matched group 1 (1/Kg body weight/every day), matched group 2 (1/Kg body weight/every day), matched group 3 (1/Kg body weight/every day), matched group 4 (1/Kg body weight/every day) and embodiment 1 low dose group (0.5/Kg body weight/every day), middle dosage group (1/Kg body weight/every day) and high dose group (2/Kg body weight/every day), every tablet quality 0.3g.
Adaptability experimentally dosed administration after growing 1 week.Per os gavage, gavage amount is 1mL/ every day, continuous 30 days, last gavage is to wine 0.14ml/10g, after giving given the test agent immediately, record mice sleep (drunk) time of grouping respectively and revive (relieving alcoholic intoxication) time, calculating tolerance time (from filling wine to time for falling asleep) and hold time (from sleep to recovery time), the results are shown in Table 1:
Table 1 compositions is on the impact of mice drunk toleration
The experimental result of matched group 1-4 differs greatly as can be seen from the table, illustrates that the present invention's component has collaborative raising effect.Sleep (drunk) time of the present invention's each dosage group, comparatively blank group was late, (from sleep to recovery time) more blank group short of holding time, and difference is extremely remarkable, increases Be very effective with dosage of the present invention., there is the time of drunk situation the latest in mouse feeding the present invention, and clear-headed within the shortest time, and therefore the present invention has the drunk function of tolerance.
2) clear-headed experiment is accelerated
Mice 18-22g, male, often organize 10, be divided into 6 groups: blank group of (distilled water, 1ml/ is every only/every day), matched group 1 (1/Kg body weight/every day), matched group 2 (1/Kg body weight/every day), matched group 3 (1/Kg body weight/every day), matched group 4 (1/Kg body weight/every day) and the embodiment of the present invention 1 low dose group (0.5/Kg body weight/every day), middle dosage group (1/Kg body weight/every day) and high dose group (2/Kg body weight/every day), every tablet quality 0.3g.
Mice adaptability experimentally dosed administration after growing 1 week.Per os gavage, gavage amount is 1ml/ every day, continuous 30 days, and after giving given the test agent 30min, gavage is to wine 0.14ml/10g, and pluck eyeball to 1.5h mice after drinking and get blood, cervical dislocation is put to death.Take liver and add normal saline and make 10% homogenate.Whole blood 37 DEG C hatches centrifugalize serum after 30min.Chromatography of gases is used to measure ethanol and acetaldehyde in mice serum.
Table 2 the present invention is on the impact of ethanol, acetaldehyde in mice serum
The present invention significantly can reduce the content of ethanol in mice serum, acetaldehyde, shows that it has significant antialcoholism action.
3) resisting fatigue experiment
Mice 18-22g, male, often organize 10, be divided into 6 groups: blank group of (distilled water, 1ml/ is only/every day often), matched group 1 (1/Kg body weight/every day), matched group 2 (1/Kg body weight/every day), matched group 3 (1/Kg body weight/every day), dosage group (1/Kg body weight/every day) in matched group 4 (1/Kg body weight/every day) and embodiment 2 ~ 6, embodiment 1 low dose group (0.5/Kg body weight/every day), middle dosage group (1/Kg body weight/every day) and high dose group (2/Kg body weight/every day), , every tablet quality 0.3g.
Mice adaptability experimentally dosed administration after growing 1 week.Per os gavage, gavage amount is 1ml/ every day, continuous 30 days, after last gives given the test agent 30min, respectively by the mice burden swimming writing time of grouping, get liver, extract glycogen, after surveying glycogen content and swimming with anthrone method, after the rest of interval, Serum lactic acid content and blood lactase acid area under curve are surveyed in blood sampling, the results are shown in Table 3-table 5
Table 3 compositions is on the impact of mice swimming time
Table 4 compositions is on the impact of Mouse Liver glycogen (g/mg)
Table 5 compositions is to mice lactic acid content variable effect
As can be seen from table 3-table 5, the swimming time of each dosage group of the present invention, hepatic glycogen content, blood lactase acid area under curve are all better than blank group, and difference is extremely remarkable.Remarkable with dose effect of the present invention, in addition, the effect of dosage group of the present invention is all obviously better than 1-4 matched group, illustrates that each group of the present invention has synergism.
Visible, mouse feeding buccal tablet of the present invention, walking weight load significant prolongation, hepatic glycogen content significantly raises, and after swimming, lactic acid content significantly declines, and therefore the present invention has the function of alleviating physical fatigue.
4) suppress to cause hepatitis experiment
Mice 18-22g, male, often organize 10, be divided into 2 groups: blank group of (normal health, 1/every only/every day), matched group (hepatocyte of Alcoholic inflammation, 1/only every/every day), mice adaptability experimentally dosed administration after growing 1 week.Per os gavage this product, gavage sample is that after 2 weeks every days of 1ml/, gavage is to wine 0.14ml/10g, and get mice lobus dexter liver 0.5 ㎝ * 0.5 ㎝ * 0.2 centimetre, sections observation, two groups of hepatic tissues are all without inflammation phenomenon.
Claims (9)
1. there is a compositions for Antialcoholic liver-protecting resisting fatigue, it is characterized in that, comprise each component of following mass parts: Cordyceps polysaccharide 10-15 part, Antrodia camphorata polysaccharide 5-10 part, Radix Panacis Quinquefolii polysaccharide 2-4 part, lycium barbarum polysaccharide 1-2 part, krestin 0.5-1 part, pachyman 1-2 part, xylitol 40-60 part.
2. the compositions with Antialcoholic liver-protecting resisting fatigue according to claim 1, it is characterized in that, comprise each component of following mass parts: Cordyceps polysaccharide 11-14 part, Antrodia camphorata polysaccharide 6-9 part, Radix Panacis Quinquefolii polysaccharide 2-3.5 part, lycium barbarum polysaccharide 1-1.5 part, krestin 0.5-1 part, pachyman 1-2 part, xylitol 45-55 part.
3. the compositions with Antialcoholic liver-protecting resisting fatigue according to claim 1, is characterized in that each component comprising following mass parts: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 2 parts, xylitol 45 parts.
4. the compositions with Antialcoholic liver-protecting resisting fatigue according to claim 1, is characterized in that each component comprising following mass parts: Cordyceps polysaccharide 14 parts, Antrodia camphorata polysaccharide 6 parts, Radix Panacis Quinquefolii polysaccharide 3 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 1 part, xylitol 50 parts.
5. the compositions with Antialcoholic liver-protecting resisting fatigue according to claim 1, is characterized in that each component comprising following mass parts: Cordyceps polysaccharide 12 parts, Antrodia camphorata polysaccharide 8 parts, Radix Panacis Quinquefolii polysaccharide 2 parts, lycium barbarum polysaccharide 1 part, krestin 0.5 part, pachyman 1 part, xylitol 60 parts.
6. the compositions with Antialcoholic liver-protecting resisting fatigue according to claim 1 is preparing the application in medicament for sobering up and protecting liver or food.
7. the compositions with Antialcoholic liver-protecting resisting fatigue according to claim 1 is preparing the application in anti-fatigue medicament or food.
8. the application according to claim 6 or 7, is characterized in that: the compositions with Antialcoholic liver-protecting resisting fatigue is made the dosage form on any one pharmaceutics.
9. the application according to claim 6 or 7, is characterized in that: make any one food form by having the compositions of Antialcoholic liver-protecting resisting fatigue and general food adjuvant and/or food additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510899872.0A CN105395702A (en) | 2015-12-09 | 2015-12-09 | Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510899872.0A CN105395702A (en) | 2015-12-09 | 2015-12-09 | Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105395702A true CN105395702A (en) | 2016-03-16 |
Family
ID=55461697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510899872.0A Pending CN105395702A (en) | 2015-12-09 | 2015-12-09 | Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105395702A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106418069A (en) * | 2016-09-12 | 2017-02-22 | 福建万亿店中店电子商务有限责任公司 | Beverage having efficacies of neutralizing effect of alcoholic drinks and protecting liver |
| CN108244658A (en) * | 2018-04-20 | 2018-07-06 | 大连军门保健食品有限公司 | A kind of alcohol-relieving and liver-protecting preparation containing witloof nutritional ingredient and preparation method thereof |
| CN109527577A (en) * | 2019-01-22 | 2019-03-29 | 广西壮仁堂生物科技有限公司 | A kind of composition with sobering up and liver protecting functions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156877A (en) * | 2007-10-08 | 2008-04-09 | 喻杉 | A sobering-up agent |
| CN104489460A (en) * | 2014-12-04 | 2015-04-08 | 赵洪卫 | Health food for protecting liver and preparation process of health food |
-
2015
- 2015-12-09 CN CN201510899872.0A patent/CN105395702A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156877A (en) * | 2007-10-08 | 2008-04-09 | 喻杉 | A sobering-up agent |
| CN104489460A (en) * | 2014-12-04 | 2015-04-08 | 赵洪卫 | Health food for protecting liver and preparation process of health food |
Non-Patent Citations (1)
| Title |
|---|
| 徐小伟等: "牛樟芝主要活性成分及其药理研究现状", 《林业调查规划》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106418069A (en) * | 2016-09-12 | 2017-02-22 | 福建万亿店中店电子商务有限责任公司 | Beverage having efficacies of neutralizing effect of alcoholic drinks and protecting liver |
| CN108244658A (en) * | 2018-04-20 | 2018-07-06 | 大连军门保健食品有限公司 | A kind of alcohol-relieving and liver-protecting preparation containing witloof nutritional ingredient and preparation method thereof |
| CN108244658B (en) * | 2018-04-20 | 2021-08-20 | 大连军门保健食品有限公司 | An anti-hangover and hepatoprotective agent containing herba Cichorii nutrients, and its preparation method |
| CN109527577A (en) * | 2019-01-22 | 2019-03-29 | 广西壮仁堂生物科技有限公司 | A kind of composition with sobering up and liver protecting functions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104721593B (en) | Fresh rhizoma Gastrodiae freeze-dried powder and preparation method | |
| CN104435748A (en) | Dendrobium officinale compound preparation as well as preparation method and application of dendrobium officinale compound preparation | |
| CN104435749A (en) | Dendrobium officinale compound preparation as well as preparation method and application of dendrobium officinale compound preparation | |
| CN106617000A (en) | Traditional Chinese medicinal composition for enhancing immunity and relieving fatigue, as well as preparation method and application of traditional Chinese medicinal composition | |
| CN102948748A (en) | Anti-fatigue health care product | |
| CN105395702A (en) | Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof | |
| CN117018125B (en) | Anti-fatigue pharmaceutical composition | |
| CN103006822B (en) | Application of American ginseng in preparing medicament for preventing and treating alcoholic liver injury | |
| CN107468747A (en) | A kind of ginseng composition for being advantageous to anticancer, anti-cancer and preparation method thereof | |
| CN107412665B (en) | It is a kind of that there is Chinese medicine composition for relieving the effect of alcohol, preventing alcoholic liver injury and its preparation method and application | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN101810337A (en) | Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali | |
| CN104474472A (en) | Broadleaf holly leaf buccal tablet capable of reducing high blood pressure, high blood lipid and high blood glucose and production method of buccal tablet | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN110876772A (en) | Preparation method and application of traditional Chinese medicine preparation with liver protection function | |
| CN105168846A (en) | Oral composition with physiological function | |
| CN105582038A (en) | Composition containing ginseng and Maca ingredients | |
| Arora | Cordyceps sinensis (berk.) sacc.-an entomophagous medicinal fungus-a review | |
| CN103961431B (en) | A kind of pharmaceutical composition that improves animal immunizing power | |
| CN104055115B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof | |
| CN103977127B (en) | A kind of Chinese medicine composition for the treatment of infantile asthma and preparation method thereof | |
| CN112057559A (en) | Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease | |
| CN103948662A (en) | Medicinal composition for strengthening animal immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160316 |